+34 620 10 75 37info@nanbiosis.com

Posts on Jan 1970

You are here : Home / 2021 / October

Dr Ramón Mangues, new member of the Royal Academy of Pharmacy of Catalonia

Dr. Ramon Mangues, head of the Oncogenesis and Antitumor Group and Scientific Director of NANBIOSIS U18 Nanotoxicology Unit of CIBER-BBN at the Sant Pau Research Institute, has been recently elected as a new member of the Royal Academy of Pharmacy of Catalonia.

The celebration will take place on November 8 at 7 pm, at the headquarters of the RAFC, (Royal Academy of Pharmacy of Catalonia) which was the headquarters of the old Hospital de la Santa Cruz since the 15th century, located at Calle del Hospital, 56, in Barcelona.

During the event, Dr. Mangues will read his admission speech “Selective delivery of drugs to metastatic stem cells“, which can be followed by zoom and live on Youtube using the following links:

• Read More

NANBIOSIS U6 opens its doors to students of Nanoscience and Nanotechnology Degree at UAB

NANBIOSIS U6, Biomaterial Processing and Nanostructuring Unit from CIBER-BBN and ICMAB-CSIC, has received today the visit of students of the 4th year degree in Nanoscience and Nanotechnology of the Auonomous University of Barcelona.

During this visit, the students had the opportunity to get known of the facilities of Unit 6 of NANBIOSIS ICTS and the to work in a research laboratory. José Amable Bernabé has, Technical Coordinator of the unit, has shown the students the equipment for processing materials with compressed fluids and also some equipment for the characterization of particulate materials.

In the Degree in Nanoscience and Nanotechnology at the UAB, students prepare to synthesize, characterize and study the properties of materials at the nanoscale; to manipulate instruments and materials of test laboratories for the study of phenomena at the nanoscale and to interpret the data obtained through experimental measurements.

Unit 6 at ICMAB-CSIC is focussec on the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. It is part of the Unique Scientific and Technical Infracstructure “NANBIOSIS”

• Read More

CIBER renews its ISO 9001: 2015 Quality Certificate for its Management System

CIBER | October 14, 2021

CIBER, the main partner of NANBIOSIS obtained, last month, the ISO 9001: 2015 accreditation, issued by the ENAC (National Accreditation Entity) through TÜV Rheinland Ibérica Inspection, Certification and Testing SA, by which the quality in the CIBER management system is certified.

The scope of the quality management system defined in the certificate covers: “Staff and training management services, administrative accounting and communication management services for the Center for Biomedical Research on the Net”.

CIBER keeps updated the Quality Management System (QMS) designed to continuously improve the effectiveness and efficiency of performance, through the consideration of the needs of the interested parties, and to increase the satisfaction perceived by its clients. .

The CIBER obtained, in September 2021, the ISO 9001: 2015 accreditation, issued by the ENAC (National Accreditation Entity) through TÜV Rheinland Ibérica Inspection, Certification and Testing SA, by which the quality in the CIBER management system.

The scope of the quality management system defined in the certificate covers: “Personnel and training management services, administrative accounting and communication management services for the Center for Biomedical Research on the Net”.

The CIBER keeps updated the Quality Management System (QMS) designed to continuously improve the effectiveness and efficiency of performance, through the consideration of the needs of the interested parties, and to increase the satisfaction perceived by its clients. .

All the documented information related to the Quality Management System (QMS) implemented in CIBER, as well as the “Quality Manual” document are available in the “Document Manager” section of the CIBER Intranet. Likewise, the CIBER “Quality Policy” can be consulted on the Transparency Portal of the Web.

• Read More

ISO 9001-2015 Quallity Management Certification for NANBIOSIS U12

NANBIOSIS U12 “Nanostructured liquid characterization unit” of IQAC-CSIC and CIBER-BBN, led by Dr. Carlos Rodriguez Abreu and D. Jordi Esquena, has implemented a Quality Management System for the scope of Technological service for characterization of colloidal dispersions, which fulfills the requirements of the standard ISO 9001:2015. An IQNet recognized certificate has been issued by AENOR last week.

This certification will expand and consolidate the service  that Unit 12 of NANBIOSIS is giving to companies and public sector researchers and facilitate their integration in cooperative international projects.

The ISO 9001 Standard is the most widespread Quality Management tool worldwide, with over one million certificates in 175 countries. The main objective of the standard is to increase customer satisfaction through continuous improvement processes. It is designed so that the organizations that apply it can guarantee their ability to offer services that meet the requirements of their customers. This international standard promotes the adoption of a process-based approach when the effectiveness of a quality management system is developed, implemented and improved, based in turn on the PDCA (Plan, Do, Check, Act) continuous improvement cycle.

The main benefits derived from ISO 9001 certification for organizations are: systematization of operations, improvement of internal organization, generation of a higher level of confidence in the internal and external environment, increased competitiveness, guarantee of compliance with legislation and regulations related to products and services, among others

• Read More

Pablo Laguna talking about Physiologically driven biomedical signal processing at the Autonomous University of San Luis Potosí

Zaragoza, October 14th, 2021 Bsicos.i3a.es

Pablo Laguna, Scientific Director of NANBIOSIS U27 High Performance Computing and researcher of BSICoS Group of I3A-UNIZAR and CIBER-BBN gave a talk about Physiologically driven biomedical signal processing at the Faculty of Physics at the Autonomous University of San Luis Potosí (UASLP) in Mexico. He explaned how biomedical signals convey information about biological systems and can emanate from sources of as varied origins as electrical, mechanical or chemical.

In particular, biomedical signals can provide relevant information on the function of the human body. This information, however, may not be apparent in the signal due to measurement noise, presence of signals coming from other interacting subsystems, or simply because it is not visible to the human eye. Signal processing is usually required to extract the relevant information from biomedical signals and convert it into meaningful data that physicians can interpret. In this respect, knowledge of the physiology behind the biomedical measurements under analysis is fundamental. Not considering the underlying physiology may lead, in the best case, to processing methods that do not fully exploit the biomedical signals being analyzed and thus extract only partially their meaningful information and, in the worst case, to processing methods that distort or even remove the information of interest in those signals.

Biomedical Signal Processing (BSP) tools are typically applied on just one particular signal recorded at a unique level of the functional system under investigation and with limited knowledge of the interrelationships with other components of that system. In most instances though, BSP can benefit from an analysis in which more than one signal is evaluated at a time (multi-modal processing), different levels of function are considered (multi-scale processing) and scientific input from different disciplines is incorporated (multi-disciplinary processing). For each problem at hand, the BSP researcher should decide up to which extent information from a number of signals, functional levels or disciplines needs to be incorporated to solve the problem.

As an example, a multi-scale model may be necessary in cases where, for instance, a deeper knowledge of the cell and tissue mechanisms underpinning alterations in a body surface signal is required, whereas a simplified single-scale model may be sufficient in other cases, as when investigating the relationship between two signals measured on the whole human body. At present, there are many biomedical signals that can be acquired and processed using relatively low-cost systems, which makes their use in the clinics very extensive. In particular, non-invasive signals readily accessible to physicians are increasingly being used to improve the diagnosis, treatment and monitoring of a variety of diseases. The presentation aims to illustrate the role played by BSP in the analysis of cardiovascular signals. A set of applications will be presented where BSP contributes to improve our knowledge on atrial and ventricular arrhythmias, the modulation of cardiac activity by the autonomic nervous system (ANS) and the interactions between cardiac and respiratory signals.

• Read More

Results of the POSITION-II Project “A pilot line for the next generation of smart catheters and implants”

Cáceres, October 14th, 2021

POSITION II has received funding within the Electronic Components and Systems for European Leadership Joint Undertaking (ECSEL JU) in collaboration with the European Union’s H2020 Framework Programme (H2020/2014-2020) and National Authorities, under grant agreement Ecsel-783132-Position-II-2017-IA.

It promotes innovation in smart medical instruments and focuses in the next generation of smart catheters and implants by the introduction of open technology platforms for: miniaturization, in-tip AD conversion, wireless communication, MEMS transducer technology and encapsulation. These platforms are open to multiple users and for multiple applications.

POSITION II will enable the further development of the European R&D and manufacturing capability, not only encompassing the micro-fabricated device itself, but also the various value chains that they enable. Finally, by bringing smart catheters into the domain of high volume manufacturing, POSITION II will improve the quality of health-care at manageable cost.

The project, led by Philips Electronics Netherlands B.V, has been developed by 45 partners located in 12 different countries and has finished in September 2021. Within this large collaborative project, the NANBIOSIS units at CCMIJU have been involved in the validation of a novel catheter to administer encapsulated cell therapy to the heart. Also NANBIOSIS U10 Drug Formulation unit of CIBER-BBN and UPV/EHU , has participated being responsible for carrying out the formulation of the cells in hydrogels, for administration through the catheter at the cardiac level, for the regeneration of heart tissue.

The results of the project are available on a video-format documentary that contains short interviews to the consortium partners on their participation. Specifically, CCMIJU has presented its work and results through a short interview to Dr. Verónica Crisóstomo, Coordinator of Cardiovascular Unit. The documentary can be found at https://vimeo.com/604674309/bd8b94050c

Further info about the project here: http://position-2.eu/

• Read More

“Ring Around the Rosy”

C2C12 myoblast cells differentiating into myotubes and adopting unusual shapes have been obtained and captured by resarchers of UAH and NANBIOSIS Unit 17 Confocal Microscopy Service (of CIBER-BBN and UAH) and and chosen photo of the month by the Spanish Society of Biochemistry and Molecular Biology (SEBBM)

The picture illustrates the month of October on the calendar that the SEBBM publishes and distributes annually among all partners, and is part of the gallery of images that illustrate the activities of the SEBBM. Likewise, the photography will participate in the “Best Scientific Image of the Year” contest. The winning image is awarded a grant to subsidize its attendance at the SEBBM Congress. Contributions participating in the contest will be exhibited in panels during the Congress

Authors:

Begoña Colás Escudero. Systems Biology Department. University of Alcalá. Mercedes Griera Merino. Systems Biology Department. University of Alcalá. M. Isabel Trabado Jiménez. Scientific Coordinator of NANBIOSIS – ICTS U17-Research Support Center in Medicine / Biology. UAH

Title: “Ring Around the Rosy”

The image is C2C12 myoblast cells differentiating into myotubes and adopting unusual shapes.

Blue marking: Hoescht-labeled cell nuclei.
Red marking: Cellular cytoskeleton labeled with Faloidin-Alexa 555 marking actin filaments of the cell.

For further information: here

• Read More

Piezoelectric-assisted micromanipulator for assisted reproduction research

Cáceres, 6/10/2021

Today the provider of a Piezoelectric-assisted micromanipulator installs this device in the CCMIJU’s Assisted Reproduction Lab and provides of specific training for its use.

The acquisition of the micromanipulator is part of the project “Embryonic Genetics in Assisted Reproduction” (GENERA), co-funded by the European Regional Development Fund (ERDF) within the framework of Spain’s Plurirregional Operational Program for Singular Scientific and Technical Infrastructures (ICTS) 2014 -2020 and by Consejería de Economía, Ciencia y Agenda Cultural of  Junta de Extremadura.

The objective of GENERA includes the purchase of three devices to expand services in the field of embryonic genetics as well as creating, editing and making traceability of embryos with high genetic value.

The first equipment acquired is the EPPENDORF PiezoXpert Piezoelectric-assisted micromanipulator that supports the creation and possible embryo editing, allowing easy penetration into cells for subsequent microinjection or micromanipulation.

This acquisition will be completed with two other devices that will offer the possibility of developing next-generation embryos, being able to face specific studies of the highest reproductive level and offering studies demanded by companies in the sector.

The project has an eligible budget of €98,000, of which the ERDF co-financing rate (80%) amounts to 78,400 and the national contribution to €21,600. It is expected to be completed in December 2022.

• Read More

Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction

Researchers of NANBIOSIS units U14 Cell Therapy unit, U21 Experimental operating rooms and U24Medical Imaging at JUMISC are coauthors of an article recently published by the journal Cells “Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction“·

Large animal studies have been carried out by the ICTS ‘NANBIOSIS’, specifically Units 14, 21, 22, and 24 of the JUMISC

Human cardiac progenitor cells (hCPC) are considered a good candidate in cell therapy for ischemic heart disease, demonstrating capacity to improve functional recovery after myocardial infarction (MI), both in small and large preclinical animal models. However, improvements are required in terms of cell engraftment and efficacy. Based on previously published reports, insulin-growth factor 1 (IGF-1) and hepatocyte growth factor (HGF) have demonstrated substantial cardioprotective, repair and regeneration activities, so they are good candidates to be evaluated in large animal model of MI. We have validated porcine cardiac progenitor cells (pCPC) and lentiviral vectors to overexpress IGF-1 (co-expressing eGFP) and HGF (co-expressing mCherry). pCPC were transduced and IGF1-eGFPpos and HGF-mCherrypos populations were purified by cell sorting and further expanded. Overexpression of IGF-1 has a limited impact on pCPC expression profile, whereas results indicated that pCPC-HGF-mCherry cultures could be counter selecting high expresser cells. In addition, pCPC-IGF1-eGFP showed a higher cardiogenic response, evaluated in co-cultures with decellularized extracellular matrix, compared with native pCPC or pCPC-HGF-mCherry. In vivo intracoronary co-administration of pCPC-IGF1-eGFP and pCPC-HFG-mCherry (1:1; 40 × 106/animal), one week after the induction of an MI model in swine, revealed no significant improvement in cardiac function.

Article: Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction Cells 2021, 10(10), 2571

• Read More